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Abstract
Helicobacter pylori infection, the most common chronic bacterial infection in the world, 
and an important cause of gastrointestinal disorders, may be involved in the pathogenesis 
of some extra-gastrointestinal disturbances, as well as an increase in blood levels of 
certain inflammatory markers. Anti-bacterial activity against Helicobacter pylori and anti-
inflammatory properties of omega-3 fatty acids have been studied in several research studies. 
The purpose of the present study was the comparison of the effects of Eicosapentaenoic 
Acid and Docosahexaenoic Acid supplementation on Helicobacter pylori eradication, serum 
levels of some inflammatory markers and total antioxidant capacity. In a randomized, 
double-blind, placebo-controlled clinical trial, 97 Helicobacter pylori positive patients (64 
patients in the two intervention groups and 33 in the control group), received 2 grams daily of 
Eicosapentaenoic Acid, Docosahexaenoic Acid or Medium Chain Triglyceride oil as placebo, 
along with conventional tetra-drug Helicobacter pylori eradication regimen, for 12 weeks. 
Helicobacter pylori eradication test and measurement of concentration of interleukine-6, 
interleukine-8, high-sensitivity C-reactive protein and total antioxidant capacity were 
performed after the intervention. There was no significant difference in eradication rate of 
the infection, levels of interleukine-6 and total antioxidant capacity among the three groups, 
while the levels of interleukine-8 and high-sensitivity C-reactive protein were statistically 
different. Eicosapentaenoic Acid or Docosahexaenoic Acid supplementation had no 
significant differential impact on the eradication of Helicobacter pylori infection, and serum 
levels of interleukine-6 and total antioxidant capacity. However, it had a desirable effect on 
the levels of interleukine-8 and high-sensitivity C-reactive protein in Helicobacter pylori 
positive patients.
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production of leukotriene B4, thromboxane A2, 
prostaglandine E1, interleukin-1, interleukin-6 
and tumor necrosis factor, n-3 FAs neutralize free 
radicals by reducing the amount of arachidonic 
acid (17). Cell culture studies have shown that 
major n-3 FAs, Eicosapentaenoic acid (EPA) and 
Docosahexaenoic acid (DHA) can also inhibit 
the production of inflammatory cytokines such 
as TNF-α, IL-1β, IL-6 and IL-8 by monocytes, 
macrophages and endothelial cells (18). 
There are a number of studies suggesting 
that EPA and DHA have anti-bacterial activity 
against H. pylori in some conditions (19-21). 
Furthermore, various studies have shown that 
EPA and DHA have different clinical effects on 
gene expression (22), blood pressure (23,24), 
vascular function (24), serum lipid profile 
(25) like triglycerides (26) and HDL-C (24), 
lipoprotein particles size like HDL-C, LDL-C 
and VDLD (24,26), serum glucose and insulin in 
hyperlipidemic male adults (25), inflammatory 
mediators (27-29), mood disorders-depression 
(30,31), visual disorders (32-35), and cognitive 
disorders-dementia (36).
Due to the high prevalence of H. pylori 
infection, consequences of untreated chronic 
infection, and that to our knowledge, no existing 
human research has addressed  differential 
effects of supplementation with long chain 
omega -3 fatty acids (EPA and DHA), on the 
eradication of this infection and the levels of 
some serum inflammatory markers in H. pylori 
positive patients, the present study was designed 
to compare the effects of EPA and DHA 
supplementation on H. pylori eradication and the 
serum levels of inflammatory markers and total 
antioxidant capacity.
Experimental
Materials and methods
The present study was a randomized, double-
blind, placebo-controlled clinical trial. The 
population of the study consisted of all adult 
patients, aged 20-60, who were admitted to the 
Gastrointestinal and Liver Disease Research 
Center of Tehran University of Medical Sciences 
(Rasool Akram Hospital). The under study 
patients were those who met the criteria of the 
study and diagnosed with H. pylori infection by a 
Introduction
Helicobacter pylori (H. pylori) infection, 
the most common chronic bacterial infection 
in the world (1), is the main etiologic factor 
of peptic ulcer and is responsible for several 
gastrointestinal disorders (2). It is the first 
bacterium known as definite carcinogen by 
the World Health Organization᾽s International 
Agency for Research on Cancer (3). While about 
half of the world population is reported to be the 
carriers of this organism (4), the prevalence of 
the infection among the adult population in the 
Middle East and Iran has been reported 70%-
90% (2) and 69% (5), respectively.
Complications of the infection depend on 
the complex interactions between the bacteria 
and the host, such as infection virulence, genetic 
sequence, the age of the host, environmental 
factors and dietary habits (6). Several studies 
have suggested that H. pylori infection may 
be involved in the pathogenesis of some extra-
gastrointestinal disturbances. This bacterium 
with the effects such as endothelial injury, 
smooth muscle proliferation, local inflammation 
of blood vessel walls (1), and the effect on lipid 
metabolism (1,2,7) is considered as a risk factor 
for cardiovascular diseases (8). The relationship 
between this bacterium and atherosclerotic 
diseases, gallbladder stone, dyspepsia, metabolic 
syndrome, type 1 diabetes mellitus and insulin 
resistance has been observed in a number of 
studies conducted in Iran (9).
Many studies have shown that H. pylori 
infection elevated production of pro-
inflammatory cytokines, regulators of immune 
and some peptide chemokines such as 
interleukin-1β (IL-1β) (10), interleukin-6 (IL-
6) (11), interleukin-8 (IL-8) (12), interleukin-12 
(IL-12) (13), tumor necrosis factor-α (TNF-α) 
(14), interferon-γ (INF-γ) (15) and high-
sensitivity C-reactive protein (hs-CRP) (16) in 
epithelial cells of the stomach. 
Omega-3 fatty acids (n-3 FAs) have shown 
to be beneficial due to their anti-inflammatory, 
anti-thrombotic, anti-arrhythmic, hypolipidemic 
and vasodilatory properties (17). N-3 FAs, by 
blocking the production of eicosanoids, derived 
from arachidonic acid, show anti-inflammatory 
actions (18). In addition to decreasing the 
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gastroenterologist on the basis of the pathological 
results of the stomach biopsy. The criteria of the 
study were: no history of treatment for H. pylori 
eradication, no stomach surgery, no history of 
peptic ulcer, no diseases causing inflammation or 
increased levels of inflammatory markers such 
as diabetes mellitus, no cardiovascular diseases, 
no pulmonary inflammations such as asthma, 
etc. Other criteria were: taking no medications 
other than those prescribed during the study 
period, taking no antibiotics or bismuth during 
the previous 2 months, taking no antioxidant 
supplements such as selenium, zinc and beta-
carotene for at least 3 months prior to the study, 
taking no omega-3 supplements for at least 
3 months prior to the study, no smoking, and 
having a BMI of less than 30. Exclusion criteria 
of the study were: changes in the type or dose 
of medication, changes in diet or daily physical 
activity, any use of antioxidant supplements and 
consumption of less than 80% of supplements 
during the study period.
The sample size was determined on the 
basis of data from previous studies (19,37,38) 
by considering type I error of 0.05 with the 
test power of 80%. To insure that the sample 
size, used in the study, could obtain the desired 
outcome for all relevant variables, the highest 
number of the calculated was considered. The 
sample size was computed as 30 per group. 
Regarding a possible loss in the follow-up, a 
safety margin of 15% was determined, therefore, 
35 patients were assigned to each group.
After attending the orientation session and 
filling out the written informed consent, the 
participants were enrolled, and 105 eligible 
patients of either sex included in the study, and 
randomly allocated in three groups. 
At the beginning of the study, information 
on socio-economic status of participants was 
collected by means of a checklist completed 
through an interview. For each person, while 
wearing light clothes, body weight was measured, 
using a SECA scale with the precision of 0.5 Kg. 
Each person’s height was measured in standing 
position without shoes, using a tape meter with 
precision of 0.5 cm. Finally, Body Mass Index 
(BMI) was calculated in the form of weight in 
kilograms divided by height in meters squared 
[weight (Kg)/height (m)2]. At the beginning of 
the study, 10 cc blood samples were obtained 
from patients after 10-12 hours of fasting.
The report of daily dietary intake was 
collected by a 24-hour diet recall questionnaire 
once before the beginning of the study, then 
in week 4, week 8 and finally at the end of the 
study. The data was then analyzed by Nutritionist 
IV software. The reports of the level of physical 
activity, at the beginning and the end of the 
study, were obtained through an interview with 
each participant, using the International Physical 
Activity Questionnaire (IPAQ). Patients were 
asked not to change their usual dietary intake 
and physical activity during the study.
Participants were randomly assigned to EPA, 
DHA or control groups, receiving 2 g daily 
morEPA, morDHA or placebo for 12 weeks, 
respectively. Each morEPA and morDHA 
supplement had a purity of 75% containing 750 
mg of n-3 FA, produced by Minami-nutrition 
Company in Belgium. MorEPA contained 580 mg 
EPA, 83 mg DHA and 87 mg other n-3 FAs, and 
morDHA contained 63 mg EPA, 465 mg DHA 
and 222 mg other n-3 FAs. The placebo, used 
in the study, was Medium Chain Triglyceride 
(MCT) oil, in 1 g capsules with a purity of 100%, 
specifically designed by Canadian company of 
Viva to resemble omega-3 capsules. Before the 
beginning of the study, all tins containing the 
capsules were coded by someone other than the 
researchers. Patients, in all three groups, received 
conventional tetra-drug H. pylori infection 
eradication regimen for 12 weeks. This drug 
protocol includes metronidazole (500 mg twice 
a day), amoxicillin (1 g twice a day), bismuth 
subcitrate (240 mg twice a day), and omeprazole 
(20 mg twice a day).
During the 12-week intervention practice, the 
patients were called to resolve possible problems 
and ensure that the participants had consumed 
the drugs and supplements. At the end of 12th 
week, the patients were asked to refer for H. 
pylori eradication check and related blood tests. 
All initial checks were repeated except height 
measurement. 
Blood samples were collected into clean 
and dry test-tubes without EDTA and the 
serum was separated by centrifugation (3000 
rpm at 4 °C for 10 min) and stored at -80°C 
for biochemical analysis. Serum levels were 
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calculated in the following ways: IL-6 and IL-8 
by ELISA method using Bendermed company 
kit from Austria and hs-CRP by ELISA method 
using IBL company kit from Germany. ELISA 
(Enzyme-linked immunosorbent assay) is a 
simple, effective assay platform used in the 
quantitative measurement of either secreted or 
intracellular protein levels in biological samples 
such as cell lysates or serum. ELISAs have 
established themselves as the gold standard for 
protein quantitation over other platforms for 
their intra- and inter-assay variability, ease of use 
and sensitivity. The ELISA platform provides a 
specific, sensitive detection of protein levels in 
non-purified samples. All of this allow for the 
accommodation of a large number of samples, in 
a fast and inexpensive platform (39).
TAC was measured by colorimetric method 
(FRAP) using TPTZ (2,4,6-tri[2-pyridyl]-
1,3,5-triazine) indicator of Sigma Company 
from U.S.A. Fluorescence Recovery After 
Photobleaching (FRAP) is the method to 
determine antioxidant capacity in extracts (40). 
FRAP method, rapidly applied, was simple 
highly and reproducible. FRAP assay depends 
upon the ferric tripyridyltriazine (Fe (III)-TPTZ) 
complex to the ferrous tripyridyltriazine (Fe (II)-
TPTZ) by a reductant at low pH. Fe (II)-TPTZ 
has an intensive blue color and can be monitored 
at 593 nm (41). 
Data entry and statistical analysis were 
performed by using SPSS
16
 software. Quantitative 
variables were reported with mean and standard 
deviation (as Mean ± SD) and their normal 
distribution was determined by Kolmogorov-
Smirnov test. To compare the infection 
eradication rate between the three groups, a 
chi-square test was performed. The difference 
in blood biochemical variables was compared, 
before and after the intervention, in each 
group. For variables with normal distribution, a 
paired t-test and for variables other than those, 
the wilcoxon test was used. To compare the 
quantitative variables, normal and non-normal 
distribution, between the three groups, Analysis 
of Variance (ANOVA) and Kruskal-wallis tests 
were used, respectively. Differences with p<0.05 
were considered significant. 
The protocol of the study was in compliance 
with the Helsinki Declaration of 1975 (revised in 
2008) and informed consent form was obtained 
from each patient. This study was approved by 
the Ethics Committee of Public Health School 
of Tehran University of Medical Sciences 
and registered in Iranian center of clinical 
trial registration with the ID number of IRCT 
201101122709N16.
Results
From 105 enrolled patients, 97 (31 in the 
EPA group, 33 in the DHA group and 33 in 
the control group) completed the study. There 
were 8 patients excluded from the study 
because of migration, adverse effects of drugs 
or supplements and refusing to continue. There 
were 12 males and 19 females in the EPA group 
with an average age of 35.54 ± 9.15 years old, 
14 males and 19 females with an average age 
of 37.09 ± 10.28 years old in the DHA group, 
and 12 males and 21 females with an average 
age of 38.60 ± 10.92 years in the control group. 
There were no significant differences between 
the intervention and control groups regarding 
the distribution of sex, age, weight, daily dietary 
intake and the level of physical activity, at the 
beginning of the study; however, the body mass 
index (BMI) was significantly different (p=0.04). 
Moreover, no significant change was observed in 
all three groups in the mean weight, BMI, daily 
dietary intake and physical activity level during 
the study period (Tables 1, 2). In addition, there 
were no significant differences between the three 
groups in the levels of biochemical variables at 
the baseline (Table 3). The rate of eradication 
of infection in the three groups receiving EPA, 
DHA and placebo was not significantly different 
after the intervention, i.e. at the end of the study 
(Table 4).
According to the findings of the study, 
there was no significant difference between 
the three groups in the average levels of IL-6 
and TAC, while the levels of IL-8 and hs-CRP 
were statistically different (p=0.03 and p=0.04, 
respectively). The results of post hoc tests 
showed significant differences between the 
patients receiving EPA and DHA supplement 
(Table 3).
In the EPA group, there was a significant 
reduction in the mean serum levels of IL-6, IL-8 
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and hs-CRP, at the end of the study as compared to 
the initial values (p=0.005, p=0.01 and p=0.002, 
respectively), while the change in the mean level 
of TAC was not significant. In the DHA group, 
there was a significant reduction in the mean 
serum levels of IL-6 and IL-8, at the end of the 
study as compared to the initial values (p=0.002 
and p=0.01, respectively), whereas the levels of 
hs-CRP and TAC did not change significantly. 
Similar to the EPA and DHA groups, there was 
a significant reduction in the serum level of IL-6 
(p=0.002) in the control group, as well (Table 3).
Discussion
The present study was conducted to compare 
the effects of Eicosapentaenoic Acid and 
Docosahexaenoic Acid supplementation on 
H. pylori eradication, serum levels of some 
inflammatory markers and total antioxidant 
capacity.
Statistical analysis of Cochran’s & Mantel-
Haenszel was applied as there was the likelihood 
that the significant difference between the three 
groups, in BMI, would have an influence, as a 
confounding variable. The results of this analysis 
suggested that the mean difference of the BMI 
of patients, in the three groups, could not be a 
confounding variable in the interpretation of the 
findings. 
As there is no evidence of previous studies on 
the effects of EPA and DHA supplements on H. 
pylori eradication, serum inflammatory markers 
and total antioxidant capacity in patients infected 
with this type of infection, the studies reporting 
findings similar to our study, were taken in to 
consideration. 
This study demonstrated that 
Eicosapentaenoic Acid or Docosahexaenoic Acid 
supplementation had no significant differential 
effect on the eradication of H. pylori infection in 
H. pylori positive patients. R. Meier et al. (2001) 
noticed that receiving a daily dosage of 1.5 g 
Eicosapen supplement instead of Metronidazole, 
along with Clarithromycin and Pantoprazole, in 
a three-drug regimen, for 7 days, was not useful 
in the eradication of the infection. This finding is 
consistent with the results of the present study. 
The findings also explained the cause of the 
effect of n-3 FAs on H. pylori eradication was the 
induction of metabolic enzymes of cytochrome 
P450 family by Eicosapen supplement resulting 
in reduction of plasma concentrations of drugs 
used to treat the infections. Several cytochrome 
P450 isoforms are responsible for metabolism of 
the drugs used by R. Meier in the eradication of 
the infection. Expression of cytochrome P450 
2C19 enzyme has recently been shown to be 
effective in eradicating H. pylori (19). Some 
studies have mentioned that the minimal rate 
of eradication of the infection, after receiving 
polyunsaturated fatty acids (PUFAs), is due to 
inadequate dose of PUFA or short duration of 
treatment (20). Thompson et al. (1994) showed 
that Helicobacter incubation in micro-aerophilic 
conditions, with a range of PUFAs such as 
linoleic acid, arachidonic acid, linolenic acid 
(n-3), linolenic acid (n-6) and eicosapenaenoic 
acid, had an inhibitory effect on the growth of the 
bacteria. In that study, almost all microorganisms 
were killed by using linolenic acid concentration 
of 0.001 M while at lower concentrations of 
PUFAs, moving of H. pylori was inhibited. 
Nevertheless, the study did not show the 
inhibitory effect of PUFAs on the growth of H. 
pylori in-vivo, which was similar to our findings. 
When incubated with gram-negative bacteria in 
anaerobic culture in-vitro, PUFAs enter into the 
outer membrane of a gram-negative organism 
and significantly increase the fluidity of the 
membrane, which explains the positive effect of 
PUFAs on the growth inhibition of Helicobacter 
species. By opening the permeability channels 
between the organism and the environment, 
concentration gradient (e.g. for hydrogen ions) 
would lead to the disintegration of the organism 
and consequently it᾽s death (21).
In the present study, it was shown that daily 
consumption of 2 g EPA and DHA capsules 
for 12 weeks did not appear to have a different 
effect on the mean level of IL-6. The average 
level of this marker decreased significantly in 
each of the three groups after the intervention 
period while this reduction was not significantly 
different in the three groups examined. Yet, the 
findings of this study showed that the mean level 
of serum IL-6, similar to the EPA and DHA 
group, reduced significantly in the control group. 
Several studies have shown that IL-6 serum 
level is high as long as H. pylori infection is 
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present, and it᾽s concentration gradually reduces 
after the treatment of the infection (42, 43). In 
our study, given that the control group as well 
as two other groups of patients had received 
medical protocol for eradication of infection, 
the observed phenomenon could be due to the 
effect of medical treatment on the level of the 
inflammatory factor. Moreover, EPA and DHA 
supplementation for 12 weeks at the dose of 2 g 
per day had a different effect on the mean serum 
level of IL-8. Although the average level of this 
indicator, in the three groups, reduced after the 
intervention period, this reduction was significant 
only in two groups receiving EPA and DHA 
supplements. EPA and DHA supplementation of 
2 g daily for 12 weeks had a different effect on 
the mean serum level of hs-CRP, as well. The 
data from Freund-Levi et al. (2009) showed no 
effect of the consumption of 4 g daily of omega-3 
supplements (containing EPA and DHA) for 6 
months on plasma levels of IL-6 and hs-CRP in 
Alzheimer᾽s patients (44). In that study, however, 
the dose and duration of supplementation were 
higher than those in our study. Moreover, the 
basic concentration of the patients' serum 
factors in that study was lower than that of our 
study while the observed reduction after the 
intervention was not statistically significant 
which might be due to the ineffectiveness of the 
intervention on the dependent variables (45). 
Contrary to the results of our study, Saifullah 
et al. (2007)  suggested that the intake of daily 
1.3 g EPA and DHA supplement in hemodialysis 
patients with the ratio of 2:1 for 12 weeks 
resulted in a significant reduction in serum CRP 
level. In that study, the basic concentration of the 
serum factors of the patients was much higher 
than that of the patients in our study, this may 
explain why despite the use of lower doses, 
the observed reduction in inflammatory factors 
was statistically significant, as the researchers 
believed that anti-inflammatory effects of n-3 
PUFAs in individuals with higher baseline CRP 
level could be detected better (37). Similar to 
the findings of our study, Barbosa et al. (2010), 
reported that parenteral intake of a mixture of 
oils, including 6.4 g of n-3 FA for 5 days in septic 
patients, caused a significant reduction in serum 
IL-6 concentration (38). Due to the high dose 
of n-3 FA and very high basic concentration of 
IL-6 in septic patients compared to the patients 
of our study, significant results were observed; 
however, the intervention period in that study 
was much shorter than our study (45). The 
mechanisms by which n-3 FAs may inhibit pro-
inflammatory cytokines production, have been 
frequently examined. The effects of n-3 PUFAs 
on inflammatory cytokines gene expression 
suggest that they might act in a way that modify 
the activity of transcription factors, most likely 
nuclear factor-κB (NF-κB) and/or peroxisome 
proliferator activated receptor (PPAR)-γ (46). 
There is a multidimensional relationship 
between NF-κB and pro-inflammatory 
cytokines. For example when the level of pro-
inflammatory cytokine TNF-α or IL-1 elevates, 
it can heighten the NF-κB action, and then 
NF-κB affects positively on the expression 
of cytokines like TNF-α itself and also IL-6, 
IL-8 and others; so the inflammatory process 
exacerbates (47). Acting in an anti-inflammatory 
manner and directly regulating inflammatory 
gene expression, PPAR-γ interferes with the 
activation of NF-κB (46), which is thought to 
have a pivotal role in immune and inflammatory 
responses through the regulation of genes 
encoding pro-inflammatory cytokines, adhesion 
molecules, chemokines, growth factors and 
inducible enzymes, such as COX2 and inducible 
nitric oxide synthase (iNOS) (27). Omega-3 
fatty acids can bind to the PPAR-α and PPAR-γ, 
which regulate the transcription of target genes. 
PPARs can also repress gene transcription by 
interfering with signaling molecules, such as 
NF-κB, thereby inhibiting the production of 
pro-inflammatory cytokines (18). The studies 
demonstrating the effects of omega-3 on serum 
inflammatory markers, have often mentioned 
these mechanisms.  
The present study has shown that EPA and 
DHA supplements, 2 g daily for 12 weeks, did 
not show to have different effects on the mean 
level of TAC. The study of Toorang et al. (2009) 
showed daily intakes of 2714 mg n-3 FAs (1548 
mg EPA and 828 mg DHA) for 8 weeks had no 
effect on the serum total antioxidant capacity 
in patients with type II diabetes mellitus (48). 
This finding is consistent with the results 
of our study. Sarbolouki et al. (2010) in the 
intervention practice, found a significant effect 
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of supplementation with 3 g EPA for 3 months 
on total antioxidant capacity and antioxidant 
enzymes in diabetic patients (49). This is also 
in line with the findings of our study. Moreover, 
Mahdavi et al. (2011) in a clinical trial discovered 
that 3 g of supplement containing 1.8 g EPA and 
1.2 g DHA for 1.5 months increased serum level 
of total antioxidant capacity and prevented the 
enhancement of oxidative stress in patients with 
gastric cancer undergoing chemotherapy (50).
Although, the differences in the results of 
aforementioned studies may be due to different 
methods used to measure this indicator, it 
should be noted that concentration of PUFAs, 
particularly EPA, is a risk factor in the 
development of oxidative stress (48).
In conclusion, present study showed that EPA 
and DHA supplementation at a dose of 2 g daily 
for 12 weeks in patients infected with H. pylori, 
had no differential effects on the eradication of 
H. pylori, mean serum levels of IL-6 and TAC, 
while it appeared to have different effects on the 
levels of IL-8 and hs-CRP.
The present study is the first of it᾽s kind, 
aimed to compare the effects of EPA and DHA on 
the eradication of H. pylori, serum concentration 
of some anti-inflammatory cytokines and total 
antioxidant capacity in infected patients, whose 
information regarding potential confounding 
variables, including dietary intake and physical 
activity level, were available. However, this 
study had limitations, as well. First, several 
patients participating in the study, were excluded 
from the study. The second limitation was lack 
of plasma level measurements of n-3 FAs for a 
better monitoring of the patients’ compliance. 
Moreover, frequent inclusion criteria, especially 
having no metabolic diseases, taking no 
supplements of omega-3 and antioxidant 
supplement and no previous history of infection, 
led to further reduction in the number of patients 
eligible for the study and hampered the disease 
finding process with many difficulties. 
Finally, it is suggested to conduct similar 
studies with higher number of patients and 
longer study period for a better observation of the 
effects of inflammatory factors. Another research 
study should be conducted with different doses 
of n-3 FAs to investigate dose-related effects of 
n-3 FAs on inflammatory markers and plasma 
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